NasdaqCM - Nasdaq Real Time Price USD

Organogenesis Holdings Inc. (ORGO)

2.3250 +0.0400 (+1.75%)
As of 10:02 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Gary S. Gillheeney Sr. President, CEO, Chair of the Board 1.06M 7.94M 1955
Mr. David C. Francisco Chief Financial Officer 473.14k -- 1966
Mr. Patrick Bilbo Chief Operating Officer 537.07k -- 1962
Ms. Lori H. Freedman B.A., Esq., J.D. Chief Administrative & Legal Officer 489.41k -- 1967
Mr. Brian Grow Chief Commercial Officer 513.06k 2.23k 1977
Mr. William R. Kolb CPA Secretary -- -- --

Organogenesis Holdings Inc.

85 Dan Road
Canton, MA 02021
United States
781 575 0775 https://organogenesis.com
Sector: 
Healthcare
Full Time Employees: 
862

Description

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Corporate Governance

Organogenesis Holdings Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 4; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024 - May 13, 2024
Organogenesis Holdings Inc. Earnings Call

Related Tickers

EVO Evotec SE
5.07
-0.59%
 
IRWD Ironwood Pharmaceuticals, Inc.
8.11
+0.37%
 
IXHL Incannex Healthcare Inc.
2.2503
-2.16%
 
AGRX Agile Therapeutics, Inc.
0.4250
+6.25%
 
LFCR Lifecore Biomedical, Inc.
6.62
-0.30%
 
INCR InterCure Ltd.
2.6449
-0.19%
 
PCRX Pacira BioSciences, Inc.
25.82
+1.27%
 
AQST Aquestive Therapeutics, Inc.
4.1701
+6.09%
 
DCPH Deciphera Pharmaceuticals, Inc.
14.32
+0.99%
 
OPTN OptiNose, Inc.
0.8278
-8.53%